x

Posted 19 August, 2021

Cyclerion Therapeutics, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:CYCN in a 8-K filed on 19 August, 2021.


  We have accepted Kevin's resignation, made in light of his expanded responsibilities and new position as President and Chief Executive Officer of Boston Children's Hospital."  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Cyclerion Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Market Cap
$7.82M
View Company Details
Cyclerion Therapeutics, Inc. by TradingView
Relevant filing section
Item 5.02. 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers


On and effective August 18, 2021, Kevin B. Churchwell, M.D., resigned from the board of directors of Cyclerion Therapeutics, Inc. (the "Company"). Dr. Churchwell did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices. 


Marsha Fanucci, the Chair of the Company's Board of Directors, noted: "I would like to sincerely thank Kevin for his years of service on the Board. We have accepted Kevin's resignation, made in light of his expanded responsibilities and new position as President and Chief Executive Officer of Boston Children's Hospital."


2